Cephalon and Ception announce positive trial results for CINQUIL

Cephalon and Ception have announced that a study into the drug CINQUIL (reslizumab), upon which the firms have been collaborating, has yielded a positive outcome.

The drug is being investigated as a treatment option for those with paediatric eosinophilic esophagitis.

Patients treated with CINQUIL demonstrated a significant reduction in esophageal eosinophil levels when compared to a placebo treatment, the study showed.

However, the study did not reach its primary endpoint, but demonstrated that that the treatment was well-tolerated.

Steve Tullman, chief executive officer at Ception, stated: “We will continue to review the data from this study and from our ongoing open-label study to find the best path forward for CINQUIL for the treatment of eosinophilic esophagitis.”

Earlier this month, Cephalon revealed that its drug Treanda (bendamustine HCI) provoked a durable response in patients suffering from relapsed indolent non-Hodgkin’s Lymphoma during trial phase.